EA200700968A1 - Фармацевтическая композиция для лечения сахарного диабета 2 типа - Google Patents

Фармацевтическая композиция для лечения сахарного диабета 2 типа

Info

Publication number
EA200700968A1
EA200700968A1 EA200700968A EA200700968A EA200700968A1 EA 200700968 A1 EA200700968 A1 EA 200700968A1 EA 200700968 A EA200700968 A EA 200700968A EA 200700968 A EA200700968 A EA 200700968A EA 200700968 A1 EA200700968 A1 EA 200700968A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes mellitus
pharmaceutical composition
treating diabetes
concentration
mellitus type
Prior art date
Application number
EA200700968A
Other languages
English (en)
Inventor
Лиза Бенинкоса
Уилльям Джаско
Original Assignee
Смитклайн Бичам Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Смитклайн Бичам Корпорейшн filed Critical Смитклайн Бичам Корпорейшн
Publication of EA200700968A1 publication Critical patent/EA200700968A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Фармацевтическая композиция для лечения сахарного диабета 2 типа и состояний, ассоциированных с сахарным диабетом, вводимая нуждающемуся в этом млекопитающему - человеку или животному - и содержащая эффективное нетоксичное количество инсулинового сенсибилизатора, такое, чтобы обеспечить концентрацию инсулинового сенсибилизатора в плазме крови по меньшей мере на пороговом уровне ("пороговая концентрация в плазме крови") в пределах интервала эффективных уровней инсулинового сенсибилизатора в плазме крови, и применение такой композиции для использования при лечении диабета 2 типа, а также используемая методология определения концентраций активного агента в плазме крови.
EA200700968A 1998-11-12 1999-11-12 Фармацевтическая композиция для лечения сахарного диабета 2 типа EA200700968A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824893.3A GB9824893D0 (en) 1998-11-12 1998-11-12 Novel method of treatment

Publications (1)

Publication Number Publication Date
EA200700968A1 true EA200700968A1 (ru) 2008-06-30

Family

ID=10842389

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200700968A EA200700968A1 (ru) 1998-11-12 1999-11-12 Фармацевтическая композиция для лечения сахарного диабета 2 типа
EA200100539A EA009192B1 (ru) 1998-11-12 1999-11-12 Способ лечения сахарного диабета типа 2

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200100539A EA009192B1 (ru) 1998-11-12 1999-11-12 Способ лечения сахарного диабета типа 2

Country Status (40)

Country Link
EP (2) EP1135128B1 (ru)
JP (1) JP2003521455A (ru)
KR (2) KR20010080440A (ru)
CN (3) CN1235586C (ru)
AP (2) AP2005003432A0 (ru)
AR (2) AR029317A1 (ru)
AT (1) ATE366573T1 (ru)
AU (1) AU768303B2 (ru)
BG (2) BG110061A (ru)
BR (1) BR9915284A (ru)
CA (1) CA2350425C (ru)
CO (1) CO5150158A1 (ru)
CY (1) CY1106892T1 (ru)
CZ (1) CZ299801B6 (ru)
DE (1) DE69936533T2 (ru)
DK (1) DK1135128T3 (ru)
DZ (1) DZ2938A1 (ru)
EA (2) EA200700968A1 (ru)
ES (1) ES2289833T3 (ru)
GB (1) GB9824893D0 (ru)
HK (1) HK1041202B (ru)
HR (1) HRP20010344B1 (ru)
HU (1) HUP0104262A3 (ru)
IL (1) IL143088A0 (ru)
MA (1) MA26759A1 (ru)
MY (1) MY128347A (ru)
NO (1) NO328391B1 (ru)
NZ (1) NZ527132A (ru)
OA (1) OA12193A (ru)
PE (1) PE20001239A1 (ru)
PL (1) PL349421A1 (ru)
PT (1) PT1135128E (ru)
RS (1) RS50130B (ru)
SK (1) SK286357B6 (ru)
TR (1) TR200101348T2 (ru)
TW (1) TWI234456B (ru)
UA (1) UA79730C2 (ru)
UY (2) UY25797A1 (ru)
WO (1) WO2000027341A2 (ru)
ZA (1) ZA200103793B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
WO2012074375A1 (en) * 2010-12-01 2012-06-07 N.V. Nutricia Prevention or treatment of overweight and obesity in type 2 diabetic patients

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH0469331A (ja) * 1990-07-10 1992-03-04 Asahi Chem Ind Co Ltd 徐放性エマルジョン製剤
JP2572673B2 (ja) * 1990-07-25 1997-01-16 エスエス製薬株式会社 徐放性錠剤
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5478853A (en) * 1992-10-12 1995-12-26 Adir Et Compagnie Thazolidinedione compounds
CA2115587A1 (en) * 1993-02-18 1994-08-19 Hayato Kihara Styrene copolymers, polystyrene compositions, processes for producing styrene copolymers, and injection-molded articles
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5708012A (en) * 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes

Also Published As

Publication number Publication date
EA009192B1 (ru) 2007-12-28
RS50130B (sr) 2009-03-25
EP1759698A1 (en) 2007-03-07
HRP20010344B1 (en) 2008-02-29
EP1135128A2 (en) 2001-09-26
OA12193A (en) 2006-05-09
YU37401A (sh) 2005-07-19
AU768303B2 (en) 2003-12-04
WO2000027341A3 (en) 2000-09-08
NZ527132A (en) 2005-01-28
CY1106892T1 (el) 2012-01-25
EA200100539A1 (ru) 2001-12-24
PE20001239A1 (es) 2000-12-24
UY25797A1 (es) 2000-12-29
JP2003521455A (ja) 2003-07-15
GB9824893D0 (en) 1999-01-06
CA2350425C (en) 2009-06-02
NO20012301D0 (no) 2001-05-10
AP1580A (en) 2006-02-24
BG105569A (en) 2002-01-31
AR029149A1 (es) 2003-06-18
MY128347A (en) 2007-01-31
CN1354661A (zh) 2002-06-19
PT1135128E (pt) 2007-10-12
BG65577B1 (bg) 2009-01-30
HUP0104262A3 (en) 2003-06-30
KR20070048279A (ko) 2007-05-08
CN1235586C (zh) 2006-01-11
HK1041202A1 (en) 2002-07-05
WO2000027341A2 (en) 2000-05-18
BR9915284A (pt) 2002-02-13
DZ2938A1 (fr) 2004-03-15
EP1135128B1 (en) 2007-07-11
CA2350425A1 (en) 2000-05-18
IL143088A0 (en) 2002-11-10
UA79730C2 (en) 2007-07-25
HUP0104262A2 (en) 2002-08-28
DE69936533T2 (de) 2008-03-13
ATE366573T1 (de) 2007-08-15
UY25801A1 (es) 2000-08-21
ES2289833T3 (es) 2008-02-01
PL349421A1 (en) 2002-07-29
AR029317A1 (es) 2003-06-25
SK286357B6 (sk) 2008-08-05
TWI234456B (en) 2005-06-21
CO5150158A1 (es) 2002-04-29
HRP20010344A2 (en) 2002-06-30
MA26759A1 (fr) 2004-12-20
TR200101348T2 (tr) 2002-02-21
CN101244062A (zh) 2008-08-20
NO20012301L (no) 2001-07-09
AP2005003432A0 (en) 2005-12-31
SK6422001A3 (en) 2001-12-03
NO328391B1 (no) 2010-02-08
AU1719600A (en) 2000-05-29
EP1135128A4 (en) 2003-07-16
DE69936533D1 (de) 2007-08-23
CZ20011656A3 (cs) 2002-06-12
DK1135128T3 (da) 2007-11-05
HK1041202B (zh) 2007-10-05
ZA200103793B (en) 2002-06-05
CZ299801B6 (cs) 2008-11-26
BG110061A (bg) 2008-12-30
KR20010080440A (ko) 2001-08-22
CN1771943A (zh) 2006-05-17

Similar Documents

Publication Publication Date Title
Yagiela et al. Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans
CY1115766T1 (el) Καθαρισμος και σταθεροποιηση πεπτιδιου και πρωτεϊνων σε φαρμακευτικους παραγοντες
EA200000041A1 (ru) Способ лечения диабета тиазолидиндионом и метформином
EA200300036A1 (ru) Комбинации ингибиторов дипептидилпептидазы iv и других антидиабетических агентов для лечения сахарного диабета
Kompa et al. Effect of different irrigating solutions on aqueous humour pH changes, intraocular pressure and histological findings after induced alkali burns
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
DE69805983T2 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
BR9808221A (pt) Método de tratamento de tumor.
EA200000042A1 (ru) Способ лечения диабета росиглитазоном и инсулином
EA200700968A1 (ru) Фармацевтическая композиция для лечения сахарного диабета 2 типа
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
RU2003113987A (ru) Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны
Rajathy Mercury in water, sediment and in some estuarine organisms of the Ennore Estuary, Madras, Tamil Nadu
KR920003977A (ko) 신장질환치료제
JPS56138112A (en) Suppository containing ascorbic acid or sodium ascorbate
KR900017599A (ko) 종양 치료용 약학 조성물
TH59780B (th) วิธีบำบัดวิธีใหม่
Saleh et al. Effect of cysteine on the hepatic toxicity and antischistosomal activity of antimonyl potassium tartrate
KR880009653A (ko) 혈액중 요산농도를 감소시키는데 유용한 치료제
KR890001555A (ko) 요산 배설용 조성물
TH59780A3 (th) วิธีบำบัดวิธีใหม่
Dagnino et al. How much epinephrine in a wash